Nutex Health (NASDAQ:NUTX) Shares Climb 13.1% – Time to Buy?

Nutex Health Inc. (NASDAQ:NUTX) shot up 13.1% on Wednesday. The stock traded as high as $203.08 and last traded at $203.0450. 92,673 shares were traded during mid-day trading, a decline of 44% from the average session volume of 166,780 shares. The stock had previously closed at $179.58.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. B. Riley Financial reissued a “buy” rating on shares of Nutex Health in a report on Friday, September 4th. Wall Street Zen downgraded Nutex Health from a “buy” rating to a “hold” rating in a research note on Saturday. Lake Street Capital reaffirmed a “buy” rating and set a $310.00 target price (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. Weiss Ratings upgraded Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 6th. Finally, Zacks Research cut Nutex Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $323.67.

Nutex Health Stock Performance

The company’s fifty day simple moving average is $203.08 and its 200 day simple moving average is $150.83. The stock has a market capitalization of $1.40 billion, a P/E ratio of 8.00 and a beta of 0.66. The company has a current ratio of 5.00, a quick ratio of 4.96 and a debt-to-equity ratio of 0.59.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported $9.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.95 by $4.43. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. The company had revenue of $210.75 million during the quarter, compared to analyst estimates of $215.03 million. As a group, sell-side analysts forecast that Nutex Health Inc. will post 26.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Nutex Health

In other Nutex Health news, Director Scott Saunders sold 203 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $214.25, for a total value of $43,492.75. Following the sale, the director owned 400 shares of the company’s stock, valued at $85,700. This trade represents a 33.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 44.68% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Nutex Health during the second quarter valued at approximately $69,612,000. Winmill & CO. Inc. bought a new position in shares of Nutex Health in the 2nd quarter worth $11,168,000. Empowered Funds LLC purchased a new stake in shares of Nutex Health during the 2nd quarter valued at $7,720,000. Bank of New York Mellon Corp purchased a new stake in shares of Nutex Health during the 2nd quarter valued at $3,956,000. Finally, Bridge City Capital LLC purchased a new stake in shares of Nutex Health during the 3rd quarter valued at $3,918,000. 5.32% of the stock is currently owned by institutional investors.

About Nutex Health

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.